ReviewMolecular cancer2020
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy.
Review in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Circulating tumor cells in peripheral blood as a diagnostic biomarker of breast cancer: A meta-analysis.Frontiers in oncology · 2023Pooled it
- Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy.JCO precision oncology · 2022Trial
- From spectroscopic analysis to clinical imaging: emerging applications and persistent challenges of raman spectroscopy in CTCs-based liquid biopsies.Annals of medicine · 2026Review
- Clinical utility of circulating tumor-derived endothelial cells in lung cancer detection and prognosis prediction.Oncology letters · 2026Article
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026Review
- Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer.BMC cancer · 2026Article
- Early Detection of Lung Cancer: A Review of Innovative Milestones and Techniques.Journal of clinical medicine · 2025Review
- Biological Nanocarriers in Cancer Therapy: Cutting Edge Innovations in Precision Drug Delivery.Biomolecules · 2025Review
- Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.Military Medical Research · 2025Review
- Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer.BMC cancer · 2024Article
- A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.The journal of liquid biopsy · 2024Review
- Review
- Nanoparticles as a novel key driver for the isolation and detection of circulating tumour cells.Scientific reports · 2024Review
- Circulating tumor cells: from new biological insights to clinical practice.Signal transduction and targeted therapy · 2024Review
- Detection of circulating tumor cells by means of machine learning using Smart-Seq2 sequencing.Scientific reports · 2024Article
- Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.International journal of molecular sciences · 2024Review
- Circulating tumor cell-derived exosome-transmitted long non-coding RNA TTN-AS1 can promote the proliferation and migration of cholangiocarcinoma cells.Journal of nanobiotechnology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.